Who Paid My Doc
Faye Tachibana
Allergy & Immunology Aiea, HI Medical Doctor
NPI 1245641448 CMS profile 4216622
98-151 Pali Momi St Ste 142, Aiea, HI 96701
General payments
$1,274
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Faye Tachibana of Aiea, HI is reported in the CMS Open Payments database as having received $1,274 across 15 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 33rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $209 | 9 | |
| 2023 | General | $320 | 3 | |
| 2022 | General | $17 | 1 | |
| 2019 | General | $729 | 2 |
Beside peers
- Faye Tachibana
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Faye Tachibana were reported at $209. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.
Show as a table
| Year | Faye Tachibana | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $729 | $594 | $163–$1,512 | $163 |
| 2020 | $0 | $426 | $106–$1,233 | $114 |
| 2021 | $0 | $638 | $157–$1,708 | $132 |
| 2022 | $17 | $790 | $205–$1,961 | $149 |
| 2023 | $320 | $852 | $220–$2,147 | $160 |
| 2024 | $0 | $865 | $203–$2,267 | $164 |
| 2025 | $209 | $1,140 | $272–$2,892 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
780
Drug cost
$636,160
Branded share of claims
62.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | Brand | 50 | $205,359 | |
| Fasenra Pen Benralizumab | Brand | 19 | $107,856 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 132 | $104,380 | |
| Tezspire Tezepelumab-Ekko | Brand | 20 | $88,192 | |
| Dupixent Syringe Dupilumab | Brand | 19 | $70,983 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 25 | $21,724 | |
| Dulera Mometasone/Formoterol | Brand | 22 | $10,110 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 11 | $4,693 | |
| Wixela Inhub Fluticasone Propion/Salmeterol | Brand | 24 | $3,463 | |
| Breyna Budesonide/Formoterol Fumarate | Brand | 19 | $2,947 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$12,519
Medicare patients
88
Services billed
181
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 64% | |
| Arthritis | 41% | |
| Chronic kidney disease | 35% | |
| COPD | 30% | |
| Osteoporosis | 30% | |
| Diabetes | 26% | |
| Atrial fibrillation | 19% | |
| Ischemic heart disease | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Allergy & Immunology in Hawaii
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Hawaii
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.